FOLH1 and pachyonychia congenita: Several series have shown that PSMA-ligand PET yields higher detection rate compared to choline-based PET-agents: A meta-analysis of Treglia et al. showed a clear benefit at PSA levels ≤ 1 ng/mL in patients with recurrent PC [8].